The most common side effects of LIBTAYO when used alone include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia). The most common side effects of LIBTAYO when ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... (2%), musculoskeletal pain (2%), rash (2%), dyspnea (1%) and pneumonitis ...

Sanofi's rash of dealmaking has continued with a $ ... are spearheaded by its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), which still has modest sales, and the drugmaker ...

They pointed to "dramatically improved" survival outcomes with immunotherapy, and objective response rates of 44% to 60% with cemiplimab (Libtayo ... was a maculopapular rash or pruritus, with ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Exposure to chlorine can cause a dry, sore rash that may burn or itch. Over-the-counter products such as hydrocortisone cream and antihistamines can help treat the rash. Chlorine is a chemical ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

CHICAGO, February 26, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company ...

They're just below thermal burn temperatures, and therefore they're causing changes in the skin and it's resulting in kind of a net-like rash." While the condition often resolves on its own within ...

fianlimab, which has shown enough promise for the company to launch four phase 3 programs, combining it with its PD-1 inhibitor Libtayo.